prednisone

JNJ

Pharma

FDA signs off on J&J's prostate cancer combo therapy Akeega

The FDA has approved Johnson & Johnson's Akeega, a combination treatment for metastatic castration-resistant prostate cancer.

Kevin Dunleavy Aug 14, 2023 11:52am

Lynparza

FDA delays review on AZ and Merck's Lynparza in prostate cancer

Dec 15, 2022 9:51am